President Donald Trump signed an executive order Saturday directing federal agencies to accelerate approval of psychedelic drugs for mental health treatment, marking the first time the FDA has offered to fast-track such substances.
The order allocates $50 million in federal funding to states developing psychedelic treatment programs and instructs the Food and Drug Administration to expedite review of drugs including psilocybin and ibogaine. The ceremony featured an unusual gathering of Trump allies, including podcaster Joe Rogan, Health Secretary Robert F. Kennedy Jr., and former Navy SEAL Marcus Luttrell.
Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life
Donald Trump, President — Al Jazeera English
Rogan, whose podcast reaches millions of listeners, has championed ibogaine as a treatment for post-traumatic stress disorder among military veterans. The substance, derived from a West African plant, remains federally banned under the most restrictive category for illegal drugs.
Sounds great. Do you want FDA approval? Let's do it
Donald Trump, in text message to Joe Rogan — Al Jazeera English
The FDA will issue national priority vouchers for three psychedelics this week, allowing certain drugs to be approved in weeks rather than years if they align with national priorities. Commissioner Marty Makary said the expedited process represents a significant shift in federal drug policy.
Trump framed the initiative as addressing a national mental health crisis affecting over 14 million American adults with serious mental illness. The Department of Veterans Affairs currently participates in at least five psychedelic trials across New York, California, and Oregon, testing treatments for PTSD among active military personnel and veterans.
Can I have some, please? I'll take some
Donald Trump, joking during ceremony — Al Jazeera English
Scientific interest in psychedelics has resurged after decades of prohibition. Government research ended in the 1960s when recreational use became widespread, but recent studies suggest therapeutic potential. A 2025 study in the Journal of the American Medical Association found that a single dose of LSD could ease anxiety and depression for months.
Kennedy has previously pledged to ease medical access to psychedelics, positioning the substances as alternatives to traditional psychiatric medications. At least 21 million American adults experience major depressive episodes annually, according to federal health data.
The bipartisan nature of psychedelic research support contrasts with other polarizing health policies. However, questions remain about implementation timelines and which specific conditions will qualify for expedited treatment protocols.
Al Jazeera frames the story as a straightforward policy development, emphasizing the bipartisan nature of psychedelic research support and providing balanced coverage of both the potential benefits and current legal restrictions. Their international perspective treats this as a significant shift in US drug policy without taking sides on the therapeutic claims.
NPR emphasizes the scientific and public health dimensions, highlighting the mental health crisis statistics and historical context of psychedelic research. Their domestic focus centers on the policy mechanics and FDA processes, presenting the initiative as a response to documented mental health needs rather than a political maneuver.
The Japan Times provides minimal coverage with a focus on the basic policy mechanics and Kennedy's role in championing alternative treatments. Their international perspective treats this as a notable but distant US policy shift, emphasizing the military veteran angle without deeper analysis of broader implications.
The coverage frames Trump's psychedelic drug order as a straightforward policy development focused on medical research acceleration, emphasizing the scientific and therapeutic potential rather than political implications. This neutral, research-focused angle reflects India's own growing interest in alternative medicine integration and pharmaceutical innovation, positioning the story as a potential model for evidence-based drug policy reform.
The framing emphasizes the tension between maintaining strict drug control categories while allowing medical exceptions, highlighting the administration's careful balance between prohibition and therapeutic access. This cautious regulatory approach resonates with Saudi Arabia's own conservative stance on controlled substances while acknowledging potential medical benefits, reflecting the kingdom's interest in modernizing healthcare within traditional frameworks.
The coverage presents the executive order as a pragmatic administrative action to expedite medical research access, focusing on the procedural aspects rather than broader drug policy implications. This technocratic framing aligns with Turkey's position as a bridge between Western medical innovation and regional healthcare needs, emphasizing practical implementation over ideological debates about drug liberalization.